The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2019 Mar 16

PMID 30874964

Citations 23

Authors

Darren S Bryan

Jessica S Donington

Affiliations

Soon will be listed here.

Abstract

Patients with locally advanced non-small cell lung cancer (NSCLC) are treated for cure, but treatment decisions are not straightforward. Chemotherapy is essential due to the high risk of systemic relapse, but local therapy is also required for cure. In the small subset of stage III patients with N0 or N1 disease, surgery is typically the initial therapy and extended resections are frequent. The majority of IIIA patients present with N2 disease and treatment paradigms for these patients are controversial, particularly concerning the role of resection. Surgery has a limited role in bulky IIIA, IIIB, and IIIC disease, which is typically treated with combined systemic therapy and radiation. The authors believe that in resectable IIIA disease, the addition of surgery to multimodality treatment appears to improve local control and overall survival. Induction therapy is essential, and the use of chemotherapy alone or chemoradiotherapy remains an area of debate. Pneumonectomy should be used with caution in IIIA disease, as numerous prospective trials have noted excessive perioperative mortality. The introduction of immunotherapies in this stage may quickly transform treatment decisions.

Citing Articles

Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function.

Yang Q, Guo Y, Guo W, Liu D, Wang H, Cai X Sci Rep. 2025; 15(1):8437.

PMID: 40069549 PMC: 11897202. DOI: 10.1038/s41598-025-92590-9.

Network meta-analysis on the efficacy and safety of management for resectable stage IIIA-N2 non-small cell lung cancer.

Yu Q, Yang H, Xiao F, Wang Z, Zhang Z, Ma Q BMC Cancer. 2024; 24(1):1286.

PMID: 39415113 PMC: 11484310. DOI: 10.1186/s12885-024-13047-2.

Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group.

Nguyen N, Page B, Giap H, Dahbi Z, Vinh-Hung V, Gorobets O Cancers (Basel). 2024; 16(17).

PMID: 39272970 PMC: 11394154. DOI: 10.3390/cancers16173112.

Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.

Deng H, Liu J, Cai X, Jiang S, Lu W, Ai Q BJS Open. 2024; 8(2).

PMID: 38513281 PMC: 10957167. DOI: 10.1093/bjsopen/zrae008.

Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.

Shao M, Xu Y, Zhang J, Mao M, Wang M Clin Transl Oncol. 2024; 26(6):1446-1458.

PMID: 38190035 DOI: 10.1007/s12094-023-03370-8.

References

Andre F, Grunenwald D, Pignon J, Dujon A, Pujol J, Brichon P . Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000; 18(16):2981-9. DOI: 10.1200/JCO.2000.18.16.2981. View

Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B . Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002; 20(1):247-53. DOI: 10.1200/JCO.2002.20.1.247. View

Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffe P, von Briel C . Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg. 2005; 27(6):1092-8. DOI: 10.1016/j.ejcts.2005.02.035. View

Casali C, Stefani A, Natali P, Rossi G, Morandi U . Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg. 2005; 28(1):33-8. DOI: 10.1016/j.ejcts.2005.03.016. View

van Meerbeeck J, Kramer G, van Schil P, Legrand C, Smit E, Schramel F . Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007; 99(6):442-50. DOI: 10.1093/jnci/djk093. View

Riquet M, Bagan P, Le Pimpec Barthes F, Banu E, Scotte F, Foucault C . Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007; 84(6):1818-24. DOI: 10.1016/j.athoracsur.2007.07.015. View

Detterbeck F . What to do with "Surprise" N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol. 2008; 3(3):289-302. DOI: 10.1097/JTO.0b013e3181630ebd. View

Thomas M, Rube C, Hoffknecht P, Macha H, Freitag L, Linder A . Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008; 9(7):636-48. DOI: 10.1016/S1470-2045(08)70156-6. View

Cheung M, Hamilton K, Sherman R, Byrne M, Nguyen D, Franceschi D . Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. Ann Surg Oncol. 2008; 16(1):3-13. DOI: 10.1245/s10434-008-0025-9. View

10.

Cerfolio R, Maniscalco L, Bryant A . The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008; 86(3):912-20. DOI: 10.1016/j.athoracsur.2008.04.073. View

11.

Kang C, Ra Y, Kim Y, Jheon S, Sung S, Kim J . The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg. 2008; 86(4):1092-7. DOI: 10.1016/j.athoracsur.2008.06.056. View

12.

Higgins K, Chino J, Marks L, Ready N, DAmico T, Clough R . Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 75(5):1462-7. DOI: 10.1016/j.ijrobp.2009.01.069. View

13.

Albain K, Swann R, Rusch V, Turrisi 3rd A, Shepherd F, Smith C . Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374(9687):379-86. PMC: 4407808. DOI: 10.1016/S0140-6736(09)60737-6. View

14.

Girard N, Mornex F, Douillard J, Bossard N, Quoix E, Beckendorf V . Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer. 2009; 69(1):86-93. DOI: 10.1016/j.lungcan.2009.10.003. View

15.

Kim A, Boffa D, Wang Z, Detterbeck F . An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2011; 143(1):55-63. DOI: 10.1016/j.jtcvs.2011.09.002. View

16.

Tanner N, Gomez M, Rainwater C, Nietert P, Simon G, Green M . Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012; 7(2):365-9. PMC: 3527069. DOI: 10.1097/JTO.0b013e31823a385f. View

17.

Pataer A, Kalhor N, Correa A, Raso M, Erasmus J, Kim E . Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012; 7(5):825-32. PMC: 3465940. DOI: 10.1097/JTO.0b013e318247504a. View

18.

Suntharalingam M, Paulus R, Edelman M, Krasna M, Burrows W, Gore E . Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell.... Int J Radiat Oncol Biol Phys. 2012; 84(2):456-63. DOI: 10.1016/j.ijrobp.2011.11.069. View

19.

Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K . A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. 2012; 118(24):6126-35. DOI: 10.1002/cncr.26689. View

20.

Veeramachaneni N, Feins R, Stephenson B, Edwards L, Fernandez F . Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012; 94(3):922-6. DOI: 10.1016/j.athoracsur.2012.04.087. View